Anders Kallin
Impact in
- Genetics top 10%
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Hematology top 10%
- Chronic Myeloid Leukemia Treatments
Papers in ⓘ
-
- NF-κB Signaling Pathways 3
- Genetics 3
- Myeloproliferative Neoplasms: Diagnosis and Treatment 3
- Co-authors
- Jean‐Baptiste Demoulin (8 shared papers)Carl‐Henrik Heldin (5 shared papers)Lars Rönnstrand (5 shared papers)Federica Toffalini (3 shared papers)Ahmed Essaghir (3 shared papers)Stefan N. Constantinescu (2 shared papers)Judith Staerk (2 shared papers)William Vainchenker (2 shared papers)
In The Last Decade
Anders Kallin
16 papers receiving 733 citations
Peers
Comparison fields: 5 of 77
- Genetics 140
- Hematology 101
- Cancer Research 112
- Molecular Biology 490
- Oncology 182
Countries citing papers authored by Anders Kallin
This map shows the geographic impact of Anders Kallin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anders Kallin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anders Kallin more than expected).
Fields of papers citing papers by Anders Kallin
This network shows the impact of papers produced by Anders Kallin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anders Kallin. The network helps show where Anders Kallin may publish in the future.
Co-authors
The 25 scholars most cited alongside Anders Kallin, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2010 | 163 | |
| 2 | 2005 | 130 | |
| 3 | 2004 | 105 | |
| 4 | 1999 | 61 | |
| 5 | 2003 | 46 | |
| 6 | 2007 | 44 | |
| 7 | 2009 | 39 | |
| 8 | 2002 | 36 | |
| 9 | 2004 | 36 | |
| 10 | 1997 | 34 | |
| 11 | 2006 | 21 | |
| 12 | 2008 | 14 | |
| 13 | 2000 | 6 | |
| 14 | 2024 | 2 | |
| 15 | 2016 | 2 | |
| 16 | [Role of PDGF and FGF receptors in cancer]. | 2010 | 1 |
About Anders Kallin
Anders Kallin is a scholar working on Cancer Research, Genetics, Rheumatology, Oncology and Immunology and Allergy, having authored 16 papers that have together received 740 indexed citations. Recurring topics across this work include Eosinophilic Disorders and Syndromes (4 papers), Cytokine Signaling Pathways and Interactions (3 papers), Protein Tyrosine Phosphatases (3 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (3 papers), NF-κB Signaling Pathways (3 papers), Cholesterol and Lipid Metabolism (2 papers), Protein Kinase Regulation and GTPase Signaling (2 papers) and Peroxisome Proliferator-Activated Receptors (2 papers). The work is most often cited by research in Genetics (140 citations), Hematology (101 citations), Cancer Research (112 citations), Molecular Biology (490 citations) and Oncology (182 citations). Anders Kallin has collaborated with scholars based in Sweden, Belgium and France. Frequent co-authors include Jean‐Baptiste Demoulin, Carl‐Henrik Heldin, Lars Rönnstrand, Federica Toffalini, Ahmed Essaghir, Stefan N. Constantinescu, Judith Staerk, William Vainchenker, Jacques van Helden and Laurent Knoops. Their work appears in journals such as Journal of Biological Chemistry, Oncogene, Journal of Lipid Research, Bioorganic & Medicinal Chemistry and Experimental Cell Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.